Amicus Therapeutics to Present at Upcoming Medical and Investor Conferences in October 2019
Upcoming Medical Conferences:
- An oral presentation highlighting Phase 1/2 results, including cohort 4, for AT-GAA for Pompe disease will be included at the 24th International
Congress of theWorld Muscle Society to be heldOctober 1-5, 2019 inCopenhagen, Denmark .
° Oral Platform Presentation:Friday, October 4 ,10:00 a.m. CEST (4:00 a.m. ET ): First-in-human study of ATB200/AT2221 in patients with Pompe disease: 24-month functional assessment results from the ATB200-02 trial –Benedikt Schoser , MD,Friedrich-Baur Institute , Deptartment of Neurology, Ludwig-Maximilians-University ofMunich, Germany .
- A poster presentation highlighting interim clinical results for the first gene therapy in CLN6 Batten disease will be included at the 48th Annual Meeting of the
Child Neurology Society to be heldOctober 23-26, 2019 inCharlotte, NC .
° Poster Sessions:Thursday, October 24 ,4:00-5:30 p.m. ET andFriday, October 25 ,7:00-8:15 a.m. ET : Interim Results from the First Clinical Gene Therapy Trial for CLN6 Batten Disease –Emily de los Reyes, MD, Pediatric Neurologist, Nationwide Children’s Hospital,Columbus, OH . (Poster #204)
Upcoming Investor Conferences:
John F. Crowley , Chairman and Chief Executive Officer, will participate in a fireside chat at theCantor Fitzgerald Global Healthcare Conference inNew York, NY onWednesday, October 2, 2019 at8:20 a.m. ET .- Amicus team members and external speakers will present during the Amicus Analyst Day on
Thursday, October 10, 2019 inNew York, NY at8:30 a.m. ET .
A live audio webcast of the presentations during the investor conferences and Amicus Analyst Day can be accessed via the Investors section of the
About
CONTACTS:
Investors:
Vice President, Investor Relations
spellegrino@amicusrx.com
(609) 662-5044
Media:
Executive Director, Corporate Communications
cbyrne@amicusrx.com
609-662-2798
FOLD–G
Source: Amicus Therapeutics, Inc.